The efficacy of ultrasound in the follow up after a negative sentinel lymph node in women with vulvar cancer: a prospective single-centre study by Pouwer, A.W. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/195634
 
 
 
Please be advised that this information was generated on 2019-06-02 and may be subject to
change.
The efficacy of ultrasound in the follow up after
a negative sentinel lymph node in women with
vulvar cancer: a prospective single-centre study
AW Pouwer,a RDM Mus,b J IntHout,c AGJ van der Zee,d J Bulten,e LFAG Massuger,a JA de Hullua
a Department of Obstetrics and Gynaecology, Radboud University Medical Center, Nijmegen, the Netherlands b Department of Radiology,
Radboud University Medical Center, Nijmegen, the Netherlands c Department of Health Evidence, Radboud Institute for Health Sciences,
Radboud University Medical Center, Nijmegen, the Netherlands d Department of Obstetrics and Gynaecology, University of Groningen,
University Medical Center Groningen, Groningen, the Netherlands e Department of Pathology, Radboud University Medical Centre, Nijmegen,
the Netherlands
Correspondence: AW Pouwer, Department of Obstetrics and Gynaecology (791), Radboud University Medical Center, PO Box 9101, 6500 HB
Nijmegen, the Netherlands. Email Anne-Floor.W.Pouwer@Radboudumc.nl
Accepted 31 May 2018. Published Online 1 August 2018.
Objective To determine the efficacy of the addition of an
ultrasound of the groins in routine follow up of women with
vulvar squamous cell carcinoma (SCC) after a negative sentinel
lymph node (SLN).
Design Prospective single-centre study.
Setting A tertiary expert oncology centre for the treatment of
vulvar cancer.
Population All women with vulvar SCC with a negative SLN,
treated between 2006 and 2014.
Methods We prospectively collected data of 139 women with
vulvar SCC treated with an SLN procedure. We analysed data of
76 patients with a negative SLN. Three-monthly follow-up visits
consisted of physical examination combined with an ultrasound of
the groins by a radiologist.
Main outcome measures The diagnostic value of ultrasound in
the follow up of women with vulvar SCC with a negative SLN
during the first 2 years after treatment.
Results During a routine visit, two asymptomatic isolated groin
recurrences were detected. Both patients were treated by
inguinofemoral lymphadenectomy and adjuvant radiotherapy and
are alive without evidence of disease 39 and 120 months after
diagnosis. In total, 348 ultrasounds and 29 fine-needle aspiration
were performed. The sensitivity of ultrasound to detect a groin
metastasis was 100% (95% CI 16–100%), and specificity was 92%
(95% CI 89–95%).
Conclusions Routine follow up including ultrasound of the groin led
to early detection of asymptomatic isolated groin recurrences. Further
research is necessary to determine the exact role of ultrasound in the
follow up of patients with vulvar SCC with a negative SLN.
Keywords Follow up, groin recurrence, sentinel lymph node
biopsy, ultrasonography, vulvar squamous cell
carcinoma.
Tweetable abstract Routine follow up including ultrasound of the
groin led to early detection of asymptomatic isolated groin
recurrences.
Please cite this paper as: Pouwer AW, Mus RDM, IntHout J, van der Zee AGJ, Bulten J, Massuger LFAG, de Hullu JA. The efficacy of ultrasound in the
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Introduction
The sentinel lymph node (SLN) procedure has been inte-
grated as standard care for a subgroup of patients with
early-stage vulvar squamous cell carcinoma (SCC) after the
publication of the GROINSS-V-I and GOG-173 studies.1,2
If the SLN contains metastatic tumour, an inguinofemoral
lymphadenectomy (IFL) is indicated. In patients with a
negative SLN, close follow up is advised with the primary
aim to identify locoregional recurrences as early as possible.
The largest long-term follow-up study of 377 patients
with an SLN for primary vulvar SCC showed isolated groin
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recurrences in 2.3% of the SLN-negative patients.3 In smal-
ler, mainly retrospective, studies, the isolated groin recur-
rence rate varied between zero and 6.6%.4,5
The main purpose of close follow up in patients with a
negative SLN was to detect groin recurrence in asymp-
tomatic patients as early as possible to achieve better sur-
vival, preferably with limited morbidity. As lymph node
palpation is difficult to interpret for small nodes, especially
in people who are overweight, the question arises whether
an ultrasound of the groins during follow up has additional
value for early detection of a groin recurrence.
There was no literature evaluating the additional value
of ultrasound in the follow up of women with vulvar
SCC with a negative SLN. The current guidelines for fol-
low up after the SLN procedure in vulvar SCC are based
on expert opinions rather than evidence. The Dutch
guideline and The European Society of Gynaecological
Oncology recommend follow up in the first 2 years,
including clinical examination of the groins, but do not
mention routine use of imaging of the groins.6,7 Further-
more, the Royal College of Obstetricians and Gynaecolo-
gists states that recognition of recurrence as early as
possible seems logical because salvage is largely dependent
on either further excision or radiotherapy. However, there
are no recommendations on performing an ultrasound or
not.8 This implies the need for more knowledge with
respect to the efficacy of an ultrasound of the groin in
the follow up after a negative SLN in patients with vulvar
SCC.
The primary aim of this study was to determine the
diagnostic value of ultrasound in the follow up of women
with vulvar SCC with a negative SLN during the first
2 years after treatment. Furthermore, our secondary aims
were to determine the adherence to the follow-up protocol
and to estimate the costs of performing ultrasound for the
detection of a recurrence.
Methods
A prospective study was performed at the Radboud Univer-
sity Medical Center, which is an expert centre for the treat-
ment of vulvar cancer. In 2006, with the knowledge of the
preliminary results of the GROINSS-V-I study (2–3% groin
recurrences with poor prognosis) combined with the evi-
dence for an ultrasound in the preoperative assessment of
the lymph node status, we decided to add ultrasound of
the groin to the routine follow up of patients with a nega-
tive SLN. We prospectively stored data of patients treated
with an SLN from 2006 until the moment of closure (end
of 2016) of the GROINSS-V-II study (NCT01500512) in an
electronic database.
We selected patients if they met all of the following
inclusion criteria: (1) primary unifocal macroinvasive
vulvar SCC with a diameter of < 4 cm and clinically non-
suspicious groin lymph nodes by palpation and without
abnormality at ultrasound and/or fine-needle aspiration
cytology (FNAC), (2) SLN treatment between 2006 and
2014, and (3) unilateral negative SLN after a unilateral pro-
cedure or bilateral negative SLN after a bilateral procedure.
Patients were not engaged in the development of our
study. The local ethical committee of the Radboud Univer-
sity Medical Center approved this study (reference number
2017-3191). There was no funding for this study.
A unilateral SLN procedure was performed in patients
with lateralised tumours (≥ 1 cm from midline) and ipsilat-
eral lymph flow on lymphoscintigraphy; in all other patients,
a bilateral SLN procedure was performed. The procedure was
performed using the combined technique (radioactive tracer
and blue dye) to identify the SLNs as described previously.9
The removed SLNs were histopathologically examined by an
expert gynaecological pathologist, including ultrastaging if
necessary.1 Patients with a (unilateral) positive SLN(s) had
an indication for further therapy of both groins.
Routine follow up consisted of a 3-monthly visit at the
outpatient clinic within the first 2 years after the SLN pro-
cedure. These visits included gynaecological examination
with palpation of the groins by the gynaecologist and a
routine ultrasound by the radiologist. In patients with a
unilateral SLN procedure, both groins were examined dur-
ing follow up. For logistical reasons, either the palpation or
the ultrasound was performed first. After the first 2 years,
follow up is less frequent (twice a year) without the perfor-
mance of a routine ultrasound of the groin.
The ultrasound of the groin was performed by our ultra-
sound unit at the Department of Radiology. This is an
expert centre with a dedicated team of professionals for the
performance of ultrasounds for different types of cancer.
Suspicious lymph nodes on ultrasound were characterised
by a short-axis diameter ≥ 10 mm in oval-shaped lymph
nodes or ≥ 8 mm in circular-shaped lymph nodes with a
malignant aspect. Malignant aspects visualised by ultrasound
are hilar hypoechogenicity, general attenuation, irregularity
of the margin, or abnormal vascular pattern on Doppler (see
Figure 3A–C). If a suspicious lymph node for metastasis was
present, FNAC was performed in the same session.
An isolated groin recurrence was defined as a histologi-
cally proven metastasis of vulvar SCC in a lymph node in
the groin, without a simultaneous local recurrence. In all
patients with an isolated groin recurrence, we reviewed the
indication for the SLN procedure and the technical aspects
of the procedure itself, and an expert pathologist reviewed
the pathological slides of the SLN(s).
Cost analysis
In our medical centre, the cost of the radiologist perform-
ing an ultrasound is €75, independent of inspecting one or
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both groins. A FNAC costs €329, including histopathologi-
cal examination.
Statistical analysis
The start of the routine follow up was defined as the date
of the SLN procedure. All routine and indicated visits
during the follow-up period, starting at 2.5 months and
going to 25.5 months after the SLN procedure, were
included for analyses. Not all visits took place exactly at
the planned time. In the analysis, we assigned the data to
the nearest targeted visit moment, using a time window of
3 months; visits occurring from 1.5 months before the
planned moment of visit till 1.5 months after the planned
moment of visit (that is, all results from the period
between 4.5 and 7.5 months) were analysed as the 6-
month visit. Only the result of the first visit, planned at
month 3, was based on a shorter time window, as data
were included from 2.5 months till 4.5 months after the
SLN procedure.
The duration of total follow up was defined as date of
the SLN procedure until date of last follow up or death.
The sensitivity, specificity, positive predictive value
(PPV), and negative predictive value (NPV) of the ultra-
sound and FNAC were calculated, and the Clopper–Pear-
son exact method was used to determine the 95% CI.10
The test characteristics of palpation of the groin were not
the aim of this study. A positive ultrasound (the presence
of suspicious lymph nodes) and a positive FNAC were con-
sidered as truly positive if histopathological examination of
the lymph nodes retrieved by IFL showed metastatic dis-
ease. A negative ultrasound or FNAC was considered as
truly negative if there was no evidence of metastatic disease
in the groin after at least 1 year of follow up.
Analyses were performed with SPSS version 22.0 (SPSS,
IBM Corp., Armonk, NY, USA).11
Results
Patient characteristics
As shown in Figure 1, 139 women underwent an SLN pro-
cedure between 2006 and 2014. We excluded 49 patients
because of a unilateral or bilateral positive SLN, two
patients because definitive histopathological examination
showed basal cell carcinoma, and another 12 patients were
excluded because they had a multifocal/larger tumour, a
technical inadequate SLN procedure, or were lost to follow
up. In conclusion, we analysed data of 76 women with a
negative SLN.
The median age was 67 years (range 37–89 years), and
the median body mass index was 25.6 kg/m2 (range 16.5–
36.1 kg/m2). A bilateral SLN procedure was performed in
58 patients; a unilateral procedure was performed in 18
patients. The median number of dissected nodes was three
(range one to seven nodes) per patient after a bilateral SLN
procedure and two (range one to four nodes) after a uni-
lateral procedure. Median total follow-up time was
47 months (range 3–142 months). For patient and tumour
characteristics, see Table 1.
Protocol adherence
Based on a schedule of 3-monthly routine visits during
2 years, the planned number of routine visits would be 608
(76 9 8). Due to shorter follow up of patients who died or
for whom vulvar cancer recurrence was detected, the
expected number of planned routine visits was 529. In
total, 408 (77% of expected) follow-up visits were per-
formed, of which 403 were routine and five were interval
visits because of complaints. Figure 2 shows the expected
number of visits and the performed number of visits with
and without an ultrasound per time period after the SLN
procedure.
During the first year, 225/279 (81%) of the expected vis-
its were performed compared with 183/250 (73%) in the
second year.
The median number of performed follow-up visits was
seven (range zero to eight visits) per patient. Four patients
did not show up at any follow-up visit for different rea-
sons: one patient had a local recurrence within 3 months
after the SLN procedure, two patients chose not to partici-
pate, and in one patient, the reason is unknown.
Figure 1. Study flow diagram. SLN, sentinel lymph node; n, number of
patients.
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As shown in Table 2, in 348 of the 408 (85%) visits, an
ultrasound was performed; 29 (8%) ultrasounds showed
one or more suspicious lymph nodes in the groin(s). As a
consequence, an FNAC was performed of all suspected
lymph nodes. In one patient, cytological examination was
inconclusive; however, there was no evidence of a groin
recurrence during a follow up at 92 months, and therefore,
the FNAC was considered to be negative. In two patients,
cytological examination of the FNAC showed a groin
recurrence (see Isolated groin recurrences). In both
patients, an ultrasound was performed during a routine
follow-up visit and a suspicious lymph node was identified
in the groin, and a subsequent FNAC was performed.
However, in one patient, there was a suspected lymph node
in the groins at palpation. All ultrasound and/or FNAC-
negative patients were followed for at least one additional
year and did not show a groin recurrence.
Isolated groin recurrences
Using ultrasound, isolated groin recurrence of the vulvar
SCC was diagnosed in two of 76 patients (2.6%); both
recurrences were diagnosed within 8 months after the SLN
procedure during a routine follow-up visit (Table 3). Groin
recurrence did not occur in any of the other patients.
One woman (see Table 3, patient A) was diagnosed with
a lateralised tumour (≥ 1 cm from midline) on the left side
of the vulva; during clinical examination and an ultrasound
of both groins, there was no suspicious lymph node identi-
fied, and a unilateral SLN procedure was performed; the
lymphoscintigram showed ipsilateral lymph flow, and two
SLNs were identified and removed. The SLN procedure was
adequate, and no substandard factors could be identified
afterwards. The patient went for a routine follow-up visit
4 months after treatment, she had no complaints, and no
abnormal lymph nodes were palpated by the gynaecologist.
However, ultrasound showed one suspicious lymph node
in the contralateral groin (see Figure 3B) and FNAC was
performed; cytological examination showed SCC.
Treatment consisted of bilateral IFL. Histopathological
examination showed five lymph nodes in the left side with-
out evidence of disease and eight lymph nodes in the right
groin; in one lymph node there was a metastasis of the
known vulvar SCC, with a diameter of 7 mm without
extranodal growth. Cloquet’s node from both the left and
right did not contain metastatic disease. Adjuvant radio-
therapy was given. This patient is alive without evidence of
disease 120 months after the diagnosis of the groin recur-
rence.
Another woman (see Table 3, patient B) was diagnosed
with a midline tumour, without suspicious groin lymph
nodes by palpation and ultrasound, and was treated by a
bilateral SLN procedure; in total, three SLNs were
Table 1. Patient and tumour characteristics
Patient and tumour characteristics Median (range) n (%)
Age (years) 67 (37–89)
Body mass index (kg/m2) 25.5 (16.5–36.1)
FIGO stage (2009)
IA 1 (1)
IB 75 (99)
Localisation
Central 58 (76)
Lateral (≥ 1 cm from midline) 18 (24)
Tumour diameter (mm) 14.5 (1.0–40.0)
Depth of invasion (mm) 3.0 (1.0–13.2)
Grade of differentiation
I 25 (33)
II 43 (57)
III 8 (10)
Number of dissected sentinel nodes per patient
Bilateral procedure 3 (1–7)
Unilateral procedure 2 (1–4)
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Figure 2. Protocol adherence. *Number of expected visits was corrected for the actual follow-up time of each patient by taking into consideration
the date of death or detection of a vulvar cancer recurrence.
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identified and removed. The procedure was adequate, and
no substandard factors could be identified afterwards.
However, 8 months later, this patient visited the outpatient
clinic for routine follow up. The gynaecologist identified a
suspicious lymph node in the right groin at palpation, and
subsequently, an ultrasound of both groins was performed.
This ultrasound showed one suspicious lymph node in the
right groin (see Figure 3C) and one suspicious lymph node
in the left groin; a FNAC of both lymph nodes was per-
formed. Cytological examination showed malignant cells
that fitted with SCC in the right groin; no evidence of
malignant disease was seen in the cytological material of
the left groin.
Bilateral IFL was performed and histopathological exami-
nation showed 17 lymph nodes from the right groin, with
one lymph node metastasis measuring 34 mm without
extranodal growth. Examination of the removed tissue of
the left groin showed 11 lymph nodes, without metastatic
disease. Adjuvant radiotherapy was performed, and the
patient is without evidence of disease 39 months after the
groin recurrence.
Test characteristics
Test characteristics of the ultrasound in the follow up were
as follows: the sensitivity of ultrasound to detect a groin
metastasis was 100% (2/2; 95% CI 16–100%), the speci-
ficity was 92% (319/346; 95% CI 89–95%), PPV 6.8% (2/
29; 95% CI 0.9–23%), and NPV 100% (346/346; 95% CI
99–100%).
For paired ultrasound and FNAC (FNAC after a positive
ultrasound), the sensitivity was 100% (2/2; 95% CI 16–
100%), specificity was 100% (27/27; 95% CI 87–100%),
and both PPV and NPV were 100% (PPV: 2/2; 95% CI
16–100%; NPV: 27/27; 95% CI 87–100%).
Costs
In this study, one isolated nonpalpable groin recurrence
was identified by the routine ultrasound of the groin. The
other groin recurrence would have been detected by a fol-
low-up regimen without a routine ultrasound of the groin,
as this recurrence was palpable during clinical examination.
The detection of the nonpalpable asymptomatic groin
recurrence required 348 ultrasounds (€26 100) and a FNAC
in 29 patients (€9541), generating total costs of €35 641.
This results in additional costs of €469 per patient.
Discussion
Main findings
We evaluated the diagnostic value of ultrasound of the
groins in the follow up of 76 women with vulvar SCC after
a negative SLN. Routine ultrasound in the follow up during
the first 2 years resulted in the early diagnosis of one
asymptomatic, nonpalpable groin recurrence. In our study,
348 ultrasounds and a FNAC in 29 patients were necessary
to detect this recurrence. The sensitivity of ultrasound to
detect a groin metastasis was 100% (95% CI 16–100%) and
specificity was 92% (95% CI 89–95%).
Table 2. Summary of results of palpation, ultrasound, and fine-needle aspiration cytology
Time after SLN
procedure
in months
Number
of visits
Number of
patients
with suspicious
groins
by palpation
Number of patients
in which ultrasound
was performed
Number of patients
with suspicious lymph
nodes on ultrasound
Number of patients
in which FNAC was
performed
Number of
patients with
positive cytologyf
3 53 2a 43 6d 6d 1
6 60 3b 52 4e 4e 1
19 59 3b 51 7e 7e 0
12 53 4c 43 3d 3d 0
15 51 1a 42 2 2 0
18 55 3c 51 4 4 0
21 45 2a 41 2 2 0
24 32 1a 25 1 1 0
Total 408 19 348 29 29 2
FNAC, fine-needle aspiration cytology; SLN, sentinel lymph node.
aIn all patients also suspicious on ultrasound.
bIn one patient not suspicious on ultrasound.
cIn two patients not suspicious on ultrasound.
dIn two patients bilateral.
eIn one patient bilateral.
fFor more detailed information, see Table 3.
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Strengths and limitations
Our prospective study is the first determining the efficacy
of ultrasound in the follow up of patients after a negative
SLN. In addition to obvious limitations, such as low num-
ber of patients and low number of events, the single-centre
design is a possible drawback. Furthermore, the ultra-
sounds were performed by different radiologists working in
our specialised ultrasound unit; this may have introduced
bias because ultrasound examination and interpretation of
the ultrasound features as the indication for a metastatic
lymph node are radiologist-dependent. However, this
reflects daily clinical practice. Furthermore, the cost analy-
ses are performed with the costs of an ultrasound and
FNAC at our Dutch medical centre and therefore may not
be reproducible for all medical centres in other countries.
Interpretation
A groin recurrence in patients with vulvar SCC is nearly
always fatal; published literature reports a 5-year survival of
only 0–10%.12–15 More recently, a 7-year survival of 50%
was reported in one study;16 this retrospective study
described all 30 patients treated for a groin recurrence (iso-
lated or a groin and pelvic recurrence). Primary groin
treatment could be either an IFL or an SLN. Follow up
consisted of clinical examination and, if needed, imaging of
the groin.
The reported 7-year survival of 50% is much higher
than the previously reported 0–10%.12–16 This might imply
that patients with a groin recurrence after a negative SLN
procedure may have a better prognosis compared with
patients with a groin recurrence after an IFL. This differ-
ence may be explained by either the (multimodal) treat-
ment options available and/or pathogenesis. An isolated
groin recurrence after an IFL can be caused by in-transit
metastases in lymph channels, as all lymph nodes are
removed. On the contrary, an isolated groin recurrence
after an SLN is more likely to be the result of remaining
(isolated) tumour cells in the lymph nodes, probably with
less spread outside the lymph node. However, all patients
with a groin recurrence after a negative SLN in the
GROINSS-V-I study, in whom follow up only consisted of
palpation of the groin, died of disease.3 In contrast, in our
study, both patients with a groin recurrence are still alive.
Therefore, early detection and resection of a groin recur-
rence, for example, by routine ultrasound, may be of
importance for improved survival.
In patients with penile SCC, the effect of early versus late
resection of lymph node metastases was evaluated.17 This
study retrospectively selected 40 patients with clinically
node-negative groin lymph node metastases treated with
lymphadenectomy. The first 20 patients were treated with a
‘wait and see’ policy and strict follow up; when the lymph
node(s) became clinically apparent and metastases were
cytologically proven, lymphadenectomy was performed.
The other 20 patients were treated using the SLN proce-
dure, and if a positive SLN was present, an additional lym-
phadenectomy was performed. The disease-specific 3-year
survival of the first group was 35% versus 84% for the sec-
ond group (P = 0.0017). These results underline the
importance of early diagnosis and resection of groin lymph
node metastases.
Table 3. Characteristics of women with an isolated groin recurrence
Patient characteristics Patient A Patient B
Age (years) 60 77
BMI (kg/m2) 27.1 23.5
Primary tumour
Tumour localisation Lateral, left Midline
FIGO stage IB IB
Tumour diameter (mm) 5 20
Depth of invasion (mm) 4.3 8.0
Grade of differentiation I II
Primary treatment
Procedure adequate
after revision
Yes Yes
Dissected SLNs
Left 2 1
Right – 2
Isolated groin recurrence
Groin recurrence Right Right
Time to recurrence (months) 3.8 7.4
Moment of diagnosis Routine visit Routine visit
Complaints No No
Palpable suspicious
lymph nodes
No Yes, right
Number of lymph
node metastases
1 1
Diameter lymph node
metastasis (mm)
7 34
Extranodal growth No No
Treatment
Bilateral inguinofemoral
lymphadenectomy
Number of lymph nodes
removed right (number of
lymph nodes with
metastatic disease)
9 (1) 17 (1)
Number of lymph
nodes removed
left (number of
lymph nodes
with metastatic disease)
6 (0) 11 (0)
Adjuvant radiotherapy Yes Yes
Survival
Patient status Alive without
evidence of disease
(120 months)
Alive without
evidence of disease
(39 months)
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Besides, the SLN procedure is also common practice in
breast cancer patients. In these patients, the axillary recur-
rence rate after a negative SLN is only 0.3%.18 This is
much lower compared with vulvar SCC and might be
explained by differences in treatment; breast cancer patients
more often receive (neo)adjuvant chemotherapy after a
negative SLN. Furthermore, Leikola et al. concluded that,
due to the low incidence of axillary recurrence, routine
ultrasound of the axilla after a negative SLN was unlikely
to be cost-effective.19
We diagnosed two isolated groin recurrences within
8 months after the SLN procedure; one might question if
the lymph node metastases have been missed in preopera-
tive workup and/or the SLN was false negative. In-depth
analyses of the indication for this SLN procedure, the pre-
operative workup and the procedure itself, revealed no sub-
standard factors. Therefore, these isolated groin recurrences
may be the result of a false-negative SLN, in which (iso-
lated) tumour cells have not been identified.
In our study, both patients with a groin recurrence were
asymptomatic and, remarkably, both patients are still alive
without evidence of disease. Since the number of patients
with a groin recurrence in our study was small, we were
not able to calculate quality-adjusted life years (QALY) and
perform a cost-effectiveness analysis. However, the ultra-
sound in patient A detected a nonpalpable groin recur-
rence, and this patient is still alive 10 years after diagnosis.
The costs for the ultrasounds and subsequent FNACs were
€35 641. Given the fact that patient A survived at least
10 years after diagnosis of the groin recurrence, the
accepted threshold (in the Netherlands) of €50 000 per
QALY is by far not reached.
To minimise the possible burden for the patient of a
false-positive ultrasound and the subsequent ‘unnecessary’
FNAC, ultrasound features that most accurately identify
groin lymph node metastasis should be identified. In
patients with breast cancer, ultrasound of the lymph nodes
in the axilla to identify metastatic lymph nodes is fre-
quently performed. In these patients, cortical thickness
(with a 3 mm cut-off) is shown to be the most reliable
ultrasound feature predicting a lymph node metastasis.20–22
This characteristic is not routinely used in the evaluation
of groin lymph nodes in patients with vulvar cancer but
might be an option.
Future follow-up schedules should be personalised and
risk-based; this can be based on body mass index, as this
patient-related factor can negatively influence the detection
of a (small) groin recurrence by palpation. More research
is needed to identify patients at high risk for a groin recur-
rence to offer a personalised risk-based follow up.
The best way to evaluate the value of using ultrasound
in terms of better survival is a randomised controlled trial
comparing a follow-up protocol with and without routine
ultrasound. However, such a trial is not realistic given the
low incidence of vulvar SCC on the one hand and the lim-
ited number of groin recurrences on the other. The most
suitable design is a prospective multicentre phase II study.
(A)
(B)
(C)
Figure 3. Ultrasound images. (A) Ultrasound image of a normal lymph
node in the groin (measurement A: 1.4 mm, B: 4.6 mm). (B)
Ultrasound image of a metastatic lymph node (patient A): enlarged
(diameter 5.9 mm), focal cortical thickening on the left side and loss of
echogenic hilar sinus fat. (C) Ultrasound image of a metastatic lymph
node (patient B): enlarged oval-shaped, loss of echogenic hilar sinus fat
(measurement A: 23.1 mm, B: 14.3 mm).
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Furthermore, with current concerns over rising healthcare
costs, further evaluation is needed to determine the most
cost-effective evidence-based follow-up schedule for
patients with a negative SLN.
Conclusion
The performance of a routine ultrasound in the follow up
of 76 women with vulvar SCC with negative SLNs resulted
in the early diagnosis of one nonpalpable groin recurrence;
this patient is still alive without evidence of disease
10 years after diagnosis. In our study, 348 ultrasounds and
29 FNACs were performed to detect this recurrence. In our
view, this is counterbalanced by the earliest possible detec-
tion of groin recurrences leading to the best possible sur-
vival for the individual patient.
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